ANI Pharmaceuticals Inc (ANIP)
65.42
-0.14
(-0.22%)
USD |
NASDAQ |
Apr 17, 16:00
65.42
0.00 (0.00%)
After-Hours: 20:00
ANI Pharmaceuticals Net Income (Quarterly): 1.155M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.155M |
| September 30, 2023 | 9.94M |
| June 30, 2023 | 6.245M |
| March 31, 2023 | 1.439M |
| December 31, 2022 | -4.243M |
| September 30, 2022 | -8.60M |
| June 30, 2022 | -14.92M |
| March 31, 2022 | -20.13M |
| December 31, 2021 | -24.14M |
| September 30, 2021 | -4.447M |
| June 30, 2021 | -14.11M |
| March 31, 2021 | 0.086M |
| December 31, 2020 | -3.635M |
| September 30, 2020 | 0.434M |
| June 30, 2020 | -12.34M |
| March 31, 2020 | -7.011M |
| December 31, 2019 | -4.835M |
| September 30, 2019 | 3.895M |
| June 30, 2019 | 6.585M |
| March 31, 2019 | 0.449M |
| December 31, 2018 | 5.43M |
| September 30, 2018 | 5.037M |
| June 30, 2018 | 2.777M |
| March 31, 2018 | 2.25M |
| December 31, 2017 | -9.629M |
| Date | Value |
|---|---|
| September 30, 2017 | 4.72M |
| June 30, 2017 | 2.681M |
| March 31, 2017 | 1.152M |
| December 31, 2016 | -1.08M |
| September 30, 2016 | 2.543M |
| June 30, 2016 | 1.125M |
| March 31, 2016 | 1.346M |
| December 31, 2015 | 2.876M |
| September 30, 2015 | 4.559M |
| June 30, 2015 | 3.571M |
| March 31, 2015 | 4.369M |
| December 31, 2014 | 21.00M |
| September 30, 2014 | 6.746M |
| June 30, 2014 | -2.363M |
| March 31, 2014 | 3.359M |
| December 31, 2013 | 3.432M |
| September 30, 2013 | 1.191M |
| June 30, 2013 | -4.583M |
| March 31, 2013 | -2.291M |
| December 31, 2012 | -3.987M |
| September 30, 2012 | -6.122M |
| June 30, 2012 | -7.344M |
| March 31, 2012 | -10.26M |
| December 31, 2011 | -6.649M |
| September 30, 2011 | -12.73M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-24.14M
Minimum
Dec 2021
9.94M
Maximum
Sep 2023
-4.664M
Average
-4.243M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| ADMA Biologics Inc | -17.64M |
| Ligand Pharmaceuticals Inc | 18.19M |
| Dentsply Sirona Inc | 67.00M |
| Allogene Therapeutics Inc | -89.26M |
| Vanda Pharmaceuticals Inc | -2.40M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 131.65M |
| Total Expenses (Quarterly) | 122.94M |
| EPS Diluted (Quarterly) | 0.02 |
| Enterprise Value | 1.471B |
| Gross Profit Margin (Quarterly) | 59.42% |
| Profit Margin (Quarterly) | 0.88% |
| Earnings Yield | 1.25% |
| Operating Earnings Yield | 4.16% |
| Normalized Earnings Yield | 1.400 |